Quantcast

Topiramate therapy for paroxysmal kinesigenic choreoathetosis.

Research paper by Yuan-Gui YG Huang, Yun-Chun YC Chen, Fang F Du, Rui R Li, Ge-Lin GL Xu, Wen W Jiang, Jing J Huang

Indexed on: 25 Sep '04Published on: 25 Sep '04Published in: Movement Disorders



Abstract

We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow-up period ranged from 8 months to 2 years. All of the patients became attack-free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect.